Drug Profile
Zika virus vaccine - Protein Sciences Corporation
Alternative Names: Zikavirus vaccineLatest Information Update: 01 Sep 2023
Price :
$50
*
At a glance
- Originator Protein Sciences Corporation
- Developer Immunobiological Technology Institute; Laboratorios Liomont; Mundo Sano; National Institute of Allergy and Infectious Diseases; Protein Sciences Corporation; Sinergium Biotech; UMN Pharma
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 01 Sep 2023 Discontinued - Preclinical for Zika virus infection (Prevention) in USA (unspecified route) (Protein Sciences Corporation pipeline; September 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Zika-virus-infection(Prevention) in USA
- 28 Feb 2021 No recent reports of development identified for research development in Zika-virus-infection(Prevention) in Brazil